Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Orion Office REIT Inc (ONL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Orion Office REIT Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.99 (market cap $4.49B), while Orion Office REIT Inc trades at $2.78 (market cap $157.99M). The key difference: ACADIA Pharmaceuticals Inc. is far larger — about 28.4× Orion Office REIT Inc's market cap, and Orion Office REIT Inc pays a 2.88% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | ONL | |
|---|---|---|
Market Cap | $4.49B | $157.99M |
Sector | Health | Real Estate |
52-Week High | $28.06 | $3.04 |
52-Week Low | $20.06 | $1.93 |
Enterprise Value | $3.69B | $641.64M |
Dividend Yield | — | 2.88% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
ONL trades at $2.78, down 1.77% on the day, with a neutral technical signal and bearish moving averages. The company shows a gross margin of 56.71% but deep net losses, with revenue declining from $208M in 2022 to $148M in 2025. Recent news highlights progress on leasing and strategic reviews, while cash flow remains positive but shrinking.
Outlook is cautious due to persistent losses and high debt, though strategic asset sales and refinancing reduce near-term risks. The 50% analyst buy rating offers some optimism, but investors face significant fundamental challenges amid the troubled office REIT sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Orion Office REIT Inc
Orion Office REIT Inc is a internally-managed REIT engaged in the ownership, acquisition, and management of a diversified portfolio of mission-critical and headquarters office buildings located in high quality suburban markets across the U.S. and leased primarily on a single-tenant net lease basis to creditworthy clients.
Read more on ONL →
